Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats

P. Palsamy, S. Subramanian

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Resveratrol is a polyphenolic phytoalexin produced in appreciable amounts as a secondary metabolite in grapevines in response to fungal infections. Based on the present knowledge, it appears to be a promising bioactive natural molecule with potential applications in phytotherapy or pharmacology. The present study was aimed to evaluate the antidiabetic properties of resveratrol in streptozotocin-nicotinamide induced experimental diabetes in rats. The diabetic rats orally treated with resveratrol (5 mg kg-1 b.w d-1) for 30 days resulted in significant (p < 0.05) decrease in the levels of blood glucose, glycosylated hemoglobin, blood urea, serum uric acid, serum creatinine and diminished activities of pathophysiological enzymes such as aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). The antihyperglycemic nature of resveratrol is also evidenced from the improvement in the levels of plasma insulin and hemoglobin. Further, the results are comparable with glyclazide, an oral standard drug. Thus, the present findings suggest that resveratrol may be considered as an effective therapeutic agent for the treatment of diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)598-605
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume62
Issue number9
DOIs
StatePublished - Nov 1 2008

Fingerprint

Niacinamide
Streptozocin
Hyperglycemia
Hypoglycemic Agents
Gliclazide
Phytotherapy
Mycoses
Glycosylated Hemoglobin A
Aspartate Aminotransferases
Uric Acid
Serum
Alanine Transaminase
Alkaline Phosphatase
Blood Glucose
Urea
Creatinine
Diabetes Mellitus
Hemoglobins
resveratrol
phytoalexins

Keywords

  • Diabetes mellitus
  • Insulin
  • Nicotinamide
  • Resveratrol
  • Streptozotocin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. / Palsamy, P.; Subramanian, S.

In: Biomedicine and Pharmacotherapy, Vol. 62, No. 9, 01.11.2008, p. 598-605.

Research output: Contribution to journalArticle

@article{8bf64b7af4d14c72b51f58d6e72fb001,
title = "Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats",
abstract = "Resveratrol is a polyphenolic phytoalexin produced in appreciable amounts as a secondary metabolite in grapevines in response to fungal infections. Based on the present knowledge, it appears to be a promising bioactive natural molecule with potential applications in phytotherapy or pharmacology. The present study was aimed to evaluate the antidiabetic properties of resveratrol in streptozotocin-nicotinamide induced experimental diabetes in rats. The diabetic rats orally treated with resveratrol (5 mg kg-1 b.w d-1) for 30 days resulted in significant (p < 0.05) decrease in the levels of blood glucose, glycosylated hemoglobin, blood urea, serum uric acid, serum creatinine and diminished activities of pathophysiological enzymes such as aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). The antihyperglycemic nature of resveratrol is also evidenced from the improvement in the levels of plasma insulin and hemoglobin. Further, the results are comparable with glyclazide, an oral standard drug. Thus, the present findings suggest that resveratrol may be considered as an effective therapeutic agent for the treatment of diabetes mellitus.",
keywords = "Diabetes mellitus, Insulin, Nicotinamide, Resveratrol, Streptozotocin",
author = "P. Palsamy and S. Subramanian",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.biopha.2008.06.037",
language = "English (US)",
volume = "62",
pages = "598--605",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "9",

}

TY - JOUR

T1 - Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats

AU - Palsamy, P.

AU - Subramanian, S.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Resveratrol is a polyphenolic phytoalexin produced in appreciable amounts as a secondary metabolite in grapevines in response to fungal infections. Based on the present knowledge, it appears to be a promising bioactive natural molecule with potential applications in phytotherapy or pharmacology. The present study was aimed to evaluate the antidiabetic properties of resveratrol in streptozotocin-nicotinamide induced experimental diabetes in rats. The diabetic rats orally treated with resveratrol (5 mg kg-1 b.w d-1) for 30 days resulted in significant (p < 0.05) decrease in the levels of blood glucose, glycosylated hemoglobin, blood urea, serum uric acid, serum creatinine and diminished activities of pathophysiological enzymes such as aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). The antihyperglycemic nature of resveratrol is also evidenced from the improvement in the levels of plasma insulin and hemoglobin. Further, the results are comparable with glyclazide, an oral standard drug. Thus, the present findings suggest that resveratrol may be considered as an effective therapeutic agent for the treatment of diabetes mellitus.

AB - Resveratrol is a polyphenolic phytoalexin produced in appreciable amounts as a secondary metabolite in grapevines in response to fungal infections. Based on the present knowledge, it appears to be a promising bioactive natural molecule with potential applications in phytotherapy or pharmacology. The present study was aimed to evaluate the antidiabetic properties of resveratrol in streptozotocin-nicotinamide induced experimental diabetes in rats. The diabetic rats orally treated with resveratrol (5 mg kg-1 b.w d-1) for 30 days resulted in significant (p < 0.05) decrease in the levels of blood glucose, glycosylated hemoglobin, blood urea, serum uric acid, serum creatinine and diminished activities of pathophysiological enzymes such as aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). The antihyperglycemic nature of resveratrol is also evidenced from the improvement in the levels of plasma insulin and hemoglobin. Further, the results are comparable with glyclazide, an oral standard drug. Thus, the present findings suggest that resveratrol may be considered as an effective therapeutic agent for the treatment of diabetes mellitus.

KW - Diabetes mellitus

KW - Insulin

KW - Nicotinamide

KW - Resveratrol

KW - Streptozotocin

UR - http://www.scopus.com/inward/record.url?scp=54049155669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049155669&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2008.06.037

DO - 10.1016/j.biopha.2008.06.037

M3 - Article

C2 - 18675532

AN - SCOPUS:54049155669

VL - 62

SP - 598

EP - 605

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 9

ER -